Follow-up patient characteristics
| Parameter | Total | non-iASD | iASD | P value |
| Months post TEER (median; IQR) | 19.5; IQR: 7.0 | 20.0; IQR: 6.0 | 19.0; IQR: 7.0 | 0.61 |
| BMI (kg/m2) | 27.0±4.3 | 26.2±4.4 | 28.2±3.9 | 0.11 |
| Systolic BP (mm Hg) | 126.4±18.8 | 130.3±18.6 | 120.8±18.1 | 0.09 |
| Diastolic BP (mm Hg) | 71.7±11.4 | 73.4±10.2 | 69.2±12.7 | 0.22 |
| NYHA Class | 1.9±0.8 | 1.75±0.9 | 2.2±0.7 | 0.09 |
| NYHA Class I | 16 (33.3) | 12 (42.9) | 4 (20.0) | 0.1 (0.09) |
| Improvement in dyspnoea, N (%) | 41 (85.4) | 22 (78.6) | 19 (95.0) | 0.21 |
| 6 MWT (m) | 308.6±96.5 | 316.5±90.8 | 297.9±105.63 | 0.55 |
| Peripheral oedema, N (%) | 8 (16.7) | 4 (14.3) | 4 (20.0) | 0.7 |
| Oedema improvement since TEER, N (%) | 11 (22.9) | 5 (17.9) | 6 (30.0) | 0.45 |
| Rehospitalisation due to heart failure, N (%) | 8 (16.7) | 3 (10.7) | 5 (25.0) | 0.25 |
| Stroke, N (%) | 3 (6.3) | 1 (3.6) | 2 (10.0) | 0.56 |
| Loop diuretics, N (%) | 32 (66.7) | 18 (64.3) | 14 (70.0) | 0.68 |
| Other diuretics, N (%) | 5 (10.4) | 3 (10.7) | 2 (10.0) | 1.0 |
| MRA, N (%) | 30 (62.5) | 16 (57.1) | 14 (70.0) | 0.36 |
| ACEI, N (%) | 18 (37.5) | 10 (35.7) | 8 (40.0) | 0.76 |
| ARB, N (%) | 12 (25.0) | 8 (28.6) | 4 (20.0) | 0.5 |
| ARNI, N (%) | 11 (22.9) | 6 (21.4) | 5 (25.0) | 1.0 |
| BB, N (%) | 42 (87.5) | 24 (85.7) | 18 (90.0) | 1.0 |
| SGLT2 inhibitor, N (%) | 4 (8.3) | 3 (10.7) | 1 (5.0) | 0.63 |
Values are mean±SD, or number (%). P values in parentheses refer to one-sided testing.
ACEI, angiotensin-converting enzyme inhibitor; ARB, AT receptor blocker; ARNI, angiotensin-neprilysin inhibitor; BB, beta-blocker; BMI, body mass index (kg/m2); BP, blood pressure; MRA, mineralocorticoid receptor antagonist; 6MWT, Six Minute Walking Test; NYHA, New York Heart Association; SGLT-2, sodium-glucose cotransporter-2.